Download PDF
Synlett 2011(12): 1673-1676  
DOI: 10.1055/s-0030-1260806
LETTER
© Georg Thieme Verlag Stuttgart ˙ New York

Total Synthesis and Cytotoxicity Evaluation of an Oxazole Analogue of Tubulysin U

Sreejith Shankar Pa, Monica Sani*b,d,, Fiona R Saundersc, Heather M Wallacec, Matteo Zanda*b,c
a Dipartimento di Chimica, Materiali e Ingegneria Chimica ‘Giulio Natta’, Politecnico di Milano, Via Mancinelli 7, 20131 Milan, Italy
b C. N. R - Istituto di Chimica del Riconoscimento Molecolare, Sezione ‘A. Quilico’, Via Mancinelli 7, 20131 Milano, Italy
c Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK Website: http://www.abdn.ac.uk/kosterlitz/
e-Mail: m.zanda@abdn.ac.uk;
d KemoTech, KemoTech s.r.l., Parco Scientifico della Sardegna, Edificio 3, Loc. Piscinamanna, 09010 Pula (CA), Italy
Further Information

Publication History

Received 25 March 2011
Publication Date:
21 June 2011 (online)

    Permissions and Reprints All articles of this category

Abstract

Tubulysins are strongly cytotoxic natural tetrapeptides with potent antiproliferative, antimitotic, and antiangiogenic activities which might find use in oncology. We herein report the first total synthesis of a stereoisomerically pure oxazole analogue of tubulysin U, which was found to be more cytotoxic than the thiazole-containing natural product. Additionally, we have developed an improved and scalable synthetic route towards the Tup fragment of the tubulysins.

Key words

tubulysin - oxazole - SAR study - chemotherapy - cytotoxicity

    References and Notes

  • 1 Sasse F. Steinmetz H. Höfle H. Reichembach H.
    J. Antibiot.  2000,  53:  879 
    CrossrefGoogle Scholar
  • 2 Steinmetz H. Glaser N. Herdtweck E. Sasse F. Reichenbach H. Höfle G. Angew. Chem. Int. Ed.  2004,  43:  4888 ; Angew. Chem. 2004, 116, 4996
    CrossrefGoogle Scholar
  • 3 For a recent study on the tubulin-bound structure of tubulysin A, see: Kubicek K. Grimm SK. Orts J. Sasse F. Carlomagno T. Angew. Chem. Int. Ed.  2010,  49:  4809 
    CrossrefGoogle Scholar
  • 4 Jackson JR. Patrick DR. Dar MM. Huang PS. Nat. Rev. Cancer  2007,  7:  107 
    CrossrefGoogle Scholar
  • 5 Höfle G. Glaser N. Leibold T. Karama U. Sasse F. Steinmetz H. Pure Appl.Chem.  2003,  75:  167 
    Google Scholar
  • 6 For a review on drug-conjugated monoclonal antibodies for the treatment of cancer, see: Lambert JM. Curr. Opin. Pharmacol.  2005,  5:  543 
    CrossrefGoogle Scholar
  • 7a Leamon CP. Reddy JA. Vetzel M. Dorton R. Westrick E. Parker N. Wang Y. Vlahov I. Cancer Res.  2008,  68:  9839 
    Google Scholar
  • 7b Vlahov IR. Wang Y. Kleindl PJ. Leamon CP. Bioorg. Med. Chem. Lett.  2008,  18:  4558 
    Google Scholar
  • 7c Reddy JA. Dorton R. Dawson A. Vetzel M. Parker N. Nicoson JS. Westrick E. Klein PJ. Wang Y. Vlahov IR. Leamon CP. Mol. Pharm.  2009,  6:  1518 
    Google Scholar
  • 7d Kularatne SA. Wang K. Santhapuram H.-KR. Low PS. Mol. Pharm.  2009,  6:  780 
    Google Scholar
  • 8a Höfle G, Leibold T, and Steinmetz H. inventors; DE  10008089. 
    Google Scholar
  • See also:
  • 8b Neri D. Fossati G. Zanda M. ChemMedChem  2006,  1:  175 
    Google Scholar
  • 9 Sani M. Fossati G. Huguenot F. Zanda M. Angew. Chem. Int. Ed.  2007,  46:  3526 
    CrossrefGoogle Scholar
  • 10a Balasubramanian R. Raghavan B. Begaye A. Sackett DL. Fecik RA. J. Med. Chem.  2009,  52:  238 
    Google Scholar
  • 10b Balasubramanian R. Raghavan B. Steele JC. Sackett DL. Fecik RA. Bioorg. Med. Chem. Lett.  2008,  18:  2996 
    Google Scholar
  • 10c Raghavan B. Balasubramanian R. Steele JC. Sackett DL. Fecik RA. J. Med. Chem.  2008,  51:  1530 
    Google Scholar
  • 10d Patterson AW. Peltier HM. Ellman JA. J. Org. Chem.  2008,  73:  4362 
    Google Scholar
  • 10e Patterson AW. Peltier HM. Sasse H. Ellman JA. Chem. Eur. J.  2007,  13:  9534 
    Google Scholar
  • 10f Wipf P. Wang Z. Org. Lett.  2007,  9:  1605 
    Google Scholar
  • 10g Chandrasekhar S. Mahipal B. Kavitha M. J. Org. Chem.  2009,  74:  9531 
    Google Scholar
  • 10h Pando O. Dörner S. Preusentanz R. Denkert A. Porzel A. Richter W. Wessjohann L. Org. Lett.  2009,  11:  5567 
    Google Scholar
  • 10i Ullrich A. Herrmann J. Müller R. Kazmaier U. Eur. J. Org. Chem.  2009,  6367 
    Google Scholar
  • 10j Peltier HM. McMahon JP. Patterson AW. Ellman JA. J. Am. Chem. Soc.  2006,  128:  16018 
    Google Scholar
  • 10k Shibue T. Hirai T. Okamoto I. Morita N. Masu H. Azumaya I. Tamura O. Chem. Eur. J.  2010,  16:  11678 
    Google Scholar
  • 10l Shibue T. Okamoto I. Morita N. Morita H. Hirasawa Y. Hosoya T. Tamura O. Bioorg. Med. Chem. Lett.  2011,  21:  431 
    Google Scholar
  • 10m Wang Z. McPherson PA. Raccor BS. Balachandran R. Zhu G. Day BW. Vogt A. Wipf P. Chem. Biol. Drug Des.  2007,  70:  75 
    Google Scholar
  • 11 Wipf P. Takada T. Rishel MJ. Org. Lett.  2004,  6:  4057 
    CrossrefGoogle Scholar
  • 12 Cheng ZZ. Hamada Y. Shioiri T. Synlett  1997,  109 
    Article in Thieme ConnectGoogle Scholar
  • 13 Phillips AJ. Uto Y. Wipf P. Reno MJ. Williams DR. Org. Lett.  2000,  2:  1165 
    CrossrefPubMedGoogle Scholar
  • 14 Barrish JC. Singh J. Spergel SH. Han W.-C. Kissick TP. Kronenthal DR. Mueller RH. J. Org. Chem.  1993,  58:  4494 
    CrossrefGoogle Scholar
  • For other methods accomplishing the mentioned transfor-mation, see:
  • 16a Williams DR. Lowder PD. Gu Y.-G. Brooks DA. Tetrahedron Lett.  1997,  38:  331 
    Google Scholar
  • 16b Chattopadhyay SK. Kempson J. McNeil A. Pattenden G. Reader M. Rippon DE. Waite D. J. Chem. Soc., Perkin Trans. 1  2000,  2415 
    Google Scholar
  • 17 Phillips AJ. Uto Y. Wipf P. Reno MJ. Williams DR. Org. Lett.  2000,  2:  1165 
    CrossrefPubMedGoogle Scholar
  • 18 Corey EJ. Helal CJ. Angew. Chem. Int. Ed.  1998,  37:  1986 ; Angew. Chem. 1998, 110, 2092
    CrossrefPubMedGoogle Scholar
  • 22 Fraser AV. Woster PM. Wallace HM. Biochem. J.  2002,  367:  307 ; and references cited therein
    CrossrefGoogle Scholar
15

Characterisation Data for Compound 4b
R f  = 0.35 (EtOAc-hexane = 3:7). ¹H NMR (400 MHz, CDCl3): δ = 8.21 (s, 1 H), 4.22 (q, J = 7.1 Hz, 2 H), 2.51 (s, 3 H), 1.19 (t, J = 7.1 Hz, 3 H). ¹³C NMR (100.5 MHz, CDCl3): δ = 185.1, 160.1, 157.6, 146.0, 134.7, 61.5, 26.6, 14.1. ESI-LCMS: m/z = 183.9 [M + H]+, 205.8 [M + Na]+.

19

Characterisation Data for Compound 5b
R f  = 0.43 (EtOAc-hexane = 45:55). FT-IR (film): νmax = 3374.8, 1734.5, 1660.4, 1505.4, 1391.9, 757.4 cm-¹. ¹H NMR (400 MHz, CDCl3): δ = 8.14 (s, 1 H), 4.84 (d, J = 10.8 Hz, 1 H), 4.72 (br s, 1 H), 4.55 (d, J = 9.3 Hz, 1 H), 4.31 (q, J = 7.1 Hz, 2 H), 3.73-3.63 (m, 1 H), 2.02 (ddd, J = 13.7, 11.3, 2.5 Hz, 1 H), 1.80-1.65 (m, 2 H), 1.38 (s, 9 H), 1.30 (t, J = 7.1 Hz, 3 H), 0.90 (d, J = 6.9 Hz, 3 H), 0.88 (d, J = 6.9 Hz, 3 H). ¹³C NMR (100.5 MHz, CDCl3): δ = 165.6, 161.1, 157.6, 143.9, 133.2, 80.1, 64.6, 61.0, 52.1, 39.1, 32.1, 28.2, 19.2, 18.2, 14.2. ESI-LCMS: m/z = 379.1 [M + Na]+.

20

Characterisation Data for Compound 21
R f  = 0.3 (MeOH-CH2Cl2 = 1:9). [α]D ²³ +8.6 (c 1.0, MeOH). ¹H NMR (400 MHz, CD3OD): δ = 7.46-7.15 (m, 5 H), 3.63 (s, 3 H), 3.59-3.47 (m, 1 H), 3.04 (dd, J = 19.9, 6.2 Hz, 1 H), 2.91 (dd, J = 13.7, 7.7 Hz, 1 H), 2.79-2.65 (m, 1 H), 2.08-1.95 (m, 1 H), 1.16 (d, J = 6.9 Hz, 3 H). ¹³C NMR (100.5 MHz, CD3OD): δ = 178.1, 137.8, 131.3, 130.9, 129.3, 53.3, 41.1, 37.9, 37.7, 18.7. ESI-LCMS: m/z = 221.9 [M + H]+.

21

Characterisation Data for the Tubulysin U Analogue oxa-1
R f  = 0.53 (MeOH-CHCl3 = 12:88). ¹H NMR (250 MHz, CD3OD): δ = 8.14 (s, 1 H), 7.19-7.00 (m, 5 H), 5.61 (dd, J = 11.1, 2.4 Hz, 1 H), 4.24-4.22 (m, 1 H), 4.10 (d, J = 8.3 Hz, 1 H), 3.90-3.75 (m, 1 H), 3.13-2.88 (m, 2 H), 2.77 (d, J = 6.6 Hz, 2 H), 2.52-2.36 (m, 2 H), 2.35 (s, 3 H), 2.27-2.09 (m, 1 H), 2.02 (s, 3 H), 1.99-1.10 (m, 13 H), 1.05 (d, J = 6.8 Hz, 3 H), 0.92-0.74 (m, 12 H). ¹³C NMR (63 MHz, CD3OD): δ = 176.7, 173.7, 173.1, 171.6, 163.4, 162.1, 143.0, 139.7, 137.5, 130.5, 129.3, 127.3, 69.5, 66.9, 59.6, 56.3, 51.8, 50.7, 44.0, 42.0, 39.3, 37.5, 35.7, 33.8, 32.7, 31.0, 25.9, 25.3, 23.5, 20.6, 19.5, 18.6, 16.2, 14.4, 11.1. ESI-LCMS: m/z = 698.2 [M + H]+, 720.2 [M + Na]+.